Portugal -
português -
INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)
drill mel e limão sem açúcar 0.2 mg + 3 mg pastilha
pierre fabre dermo-cosmétique portugal, lda. - tetracaína + cloro-hexidina - pastilha - 0.2 mg + 3 mg - cloro-hexidina, gluconato 3 mg ; tetracaína, cloridrato 0.2 mg - antiseptics - n/a - duração do tratamento: curta ou média duração
Portugal -
português -
INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)
drill sem açúcar 0.2 mg + 3 mg pastilha
pierre fabre dermo-cosmétique portugal, lda. - tetracaína + cloro-hexidina - pastilha - 0.2 mg + 3 mg - cloro-hexidina, gluconato 3 mg ; tetracaína, cloridrato 0.2 mg - antiseptics - n/a - duração do tratamento: curta ou média duração
Portugal -
português -
INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)
drill eucalipto sem açúcar 0.2 mg + 3 mg pastilha
pierre fabre dermo-cosmétique portugal, lda. - tetracaína + cloro-hexidina - pastilha - 0.2 mg + 3 mg - cloro-hexidina, gluconato 3 mg ; tetracaína, cloridrato 0.2 mg - throat preparations - n/a - duração do tratamento: curta ou média duração
União Europeia -
português -
EMA (European Medicines Agency)
dupixent
sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agentes para dermatite, excluindo corticosteróides - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
Brasil -
português -
ANVISA (Agência Nacional de Vigilância Sanitária)
alerfin
chiesi farmacÊutica ltda - dipropionato de beclometasona - corticosteroides topicos
Brasil -
português -
ANVISA (Agência Nacional de Vigilância Sanitária)
benevat
laboratÓrio teuto brasileiro s/a - valerato de betametasona - corticosteroides topicos
Brasil -
português -
ANVISA (Agência Nacional de Vigilância Sanitária)
clob-x
galderma brasil ltda - propionato de clobetasol - corticosteroides topicos
Brasil -
português -
ANVISA (Agência Nacional de Vigilância Sanitária)
clobesol
valeant farmacÊutica do brasil ltda - propionato de clobetasol - corticosteroides topicos